Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details
Iambic Therapeutics has filed to go public and says it could move IAM1363, its lead drug targeting HER2 cancers, into a registrational trial as early as next year.
Iambic Therapeutics
Private
AI-driven small molecule drug discovery company whose Enchant platform combines generative models such as NeuralPLexer with high-throughput experimentation to design therapeutics; partnered with AbbVie and Revolution Medicines.
Company Info
Sector:AI Drug Discovery
Headquarters:San Diego, California, USA
Founded:2019
Website:www.iambic.ai/
Funding Round:Series B
Total Funding:~$150M
Upcoming Milestones & Key Dates
2026
Partnership
AbbVie R&D collaboration on Enchant v3-discovered small molecules
Clinical Development Pipeline
Enchant (AI discovery platform)
Target: AI/ML generative platformIAM1363
Target: HER2Recent News
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
Iambic releases next version of its Enchant model, signs deal with AbbVie
Iambic launched Enchant v3, a 41-billion-parameter AI model, and signed an R&D deal with AbbVie covering small molecules in immunology, neuroscience and oncology.
Leadership Team
Tom Miller
Co-Founder and Chief Executive Officer
Fred Manby
Co-Founder and Chief Technology Officer
Neil Josephson
Chief Medical Officer